KemPharm, Inc. (NASDAQ:KMPH – Get Rating) CEO Travis C. Mickle acquired 3,000 shares of the company’s stock in a transaction that occurred on Wednesday, May 25th. The stock was purchased at an average price of $4.37 per share, for a total transaction of $13,110.00. Following the acquisition, the chief executive officer now directly owns 39,521 shares of the company’s stock, valued at approximately $172,706.77. The purchase was disclosed in a filing with the SEC, which is accessible through this link.
Shares of KMPH traded down $0.10 during mid-day trading on Wednesday, hitting $4.42. The company’s stock had a trading volume of 286,473 shares, compared to its average volume of 525,730. KemPharm, Inc. has a one year low of $4.00 and a one year high of $15.70. The stock’s 50-day moving average is $4.72 and its two-hundred day moving average is $6.48.
KemPharm (NASDAQ:KMPH – Get Rating) last issued its earnings results on Wednesday, March 30th. The specialty pharmaceutical company reported ($0.08) EPS for the quarter, hitting the consensus estimate of ($0.08). KemPharm had a negative return on equity of 0.28% and a negative net margin of 0.60%. Equities analysts predict that KemPharm, Inc. will post -0.23 EPS for the current year.
Several brokerages have commented on KMPH. Zacks Investment Research upgraded KemPharm from a “sell” rating to a “hold” rating in a report on Tuesday. HC Wainwright upgraded KemPharm from a “neutral” rating to a “buy” rating and increased their price target for the company from $10.00 to $11.00 in a report on Monday, January 31st. Finally, StockNews.com began coverage on KemPharm in a report on Thursday, March 31st. They set a “hold” rating on the stock.
KemPharm Company Profile (Get Rating)
KemPharm, Inc, a specialty pharmaceutical company, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds that may have applications for new disease indications.
- Get a free copy of the StockNews.com research report on KemPharm (KMPH)
- Short-Covering Begins In Big Lots
- Institutions Ring The Register On Toll Brothers Stock
- Agilent Technologies Is Bottoming But Don’t Buy It Yet
- Dick’s Sporting Goods Falls Flat On Weak Guidance
- Indie Semiconductor Stock is Putting in a Bottom
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for KemPharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm and related companies with MarketBeat.com's FREE daily email newsletter.